Published in PLoS One on September 06, 2012
Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest (2014) 2.39
The Collaborative Cross as a resource for modeling human disease: CC011/Unc, a new mouse model for spontaneous colitis. Mamm Genome (2014) 1.09
Nox1 causes ileocolitis in mice deficient in glutathione peroxidase-1 and -2. Free Radic Biol Med (2013) 0.81
The Gdac1 locus modifies spontaneous and Salmonella-induced colitis in mice deficient in either Gpx2 or Gpx1 gene. Free Radic Biol Med (2013) 0.80
Deficiency in Duox2 activity alleviates ileitis in GPx1- and GPx2-knockout mice without affecting apoptosis incidence in the crypt epithelium. Redox Biol (2016) 0.75
The oxido-reductase enzyme glutathione peroxidase 4 (GPX4) governs Salmonella Typhimurium-induced neutrophil transepithelial migration. Cell Microbiol (2014) 0.75
Group III phospholipase A2 promotes colitis and colorectal cancer. Sci Rep (2017) 0.75
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
R/qtl: QTL mapping in experimental crosses. Bioinformatics (2003) 22.38
SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Science (2005) 12.02
The gastrointestinal epithelium and its autochthonous bacterial flora. J Exp Med (1968) 10.84
Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol (2011) 7.84
Genetics and pathogenesis of inflammatory bowel disease. Nature (2011) 7.79
Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science (2010) 4.69
The Mouse Genome Database (MGD): premier model organism resource for mammalian genomics and genetics. Nucleic Acids Res (2010) 4.58
p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol Cell Biol (2003) 4.36
A direct role for dual oxidase in Drosophila gut immunity. Science (2005) 4.24
The expression profile of microRNAs in mouse embryos. Nucleic Acids Res (2006) 3.49
Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. FASEB J (2003) 3.44
CEP152 is a genome maintenance protein disrupted in Seckel syndrome. Nat Genet (2010) 3.25
Human Blinkin/AF15q14 is required for chromosome alignment and the mitotic checkpoint through direct interaction with Bub1 and BubR1. Dev Cell (2007) 3.06
Dll1- and dll4-mediated notch signaling are required for homeostasis of intestinal stem cells. Gastroenterology (2011) 2.94
Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci U S A (1999) 2.80
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80
miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci U S A (2009) 2.74
Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res (2004) 2.42
A voltage-gated ion channel expressed specifically in spermatozoa. Proc Natl Acad Sci U S A (2001) 2.37
Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci (2007) 2.28
Properties of the Group IV phospholipase A2 family. Prog Lipid Res (2006) 2.27
53BP1: function and mechanisms of focal recruitment. Biochem Soc Trans (2009) 1.90
A novel gene involved in zinc transport is deficient in the lethal milk mouse. Nat Genet (1997) 1.88
The GI-GPx gene is a target for Nrf2. Mol Cell Biol (2005) 1.85
Polyamine catabolism and disease. Biochem J (2009) 1.79
Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. PLoS Genet (2008) 1.78
CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP cascade. J Immunol (2009) 1.70
Blood meal-derived heme decreases ROS levels in the midgut of Aedes aegypti and allows proliferation of intestinal microbiota. PLoS Pathog (2011) 1.57
DUOX2-derived reactive oxygen species are effectors of NOD2-mediated antibacterial responses. J Cell Sci (2009) 1.56
A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet (2011) 1.54
Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol (2000) 1.54
COP9 signalosome subunit 8 is essential for peripheral T cell homeostasis and antigen receptor-induced entry into the cell cycle from quiescence. Nat Immunol (2007) 1.48
Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene (2006) 1.47
Disruption of the COP9 signalosome Csn2 subunit in mice causes deficient cell proliferation, accumulation of p53 and cyclin E, and early embryonic death. Mol Cell Biol (2003) 1.46
Expression, characterization, and tissue distribution of a new cellular selenium-dependent glutathione peroxidase, GSHPx-GI. J Biol Chem (1993) 1.43
Roles of phospholipase C beta2 in chemoattractant-elicited responses. Proc Natl Acad Sci U S A (1997) 1.43
Essential requirement of cytosolic phospholipase A2 for activation of the phagocyte NADPH oxidase. J Biol Chem (1998) 1.39
Stereocilin-deficient mice reveal the origin of cochlear waveform distortions. Nature (2008) 1.39
Mechanisms and function of DUOX in epithelia of the lung. Antioxid Redox Signal (2009) 1.38
SLC24A5 encodes a trans-Golgi network protein with potassium-dependent sodium-calcium exchange activity that regulates human epidermal melanogenesis. J Biol Chem (2007) 1.37
A combined functional annotation score for non-synonymous variants. Hum Hered (2012) 1.37
Ce-Duox1/BLI-3 generates reactive oxygen species as a protective innate immune mechanism in Caenorhabditis elegans. Infect Immun (2009) 1.37
Duox maturation factors form cell surface complexes with Duox affecting the specificity of reactive oxygen species generation. FASEB J (2008) 1.36
Sensorineural deafness and male infertility: a contiguous gene deletion syndrome. J Med Genet (2006) 1.36
Network for activation of human endothelial cells by oxidized phospholipids: a critical role of heme oxygenase 1. Circ Res (2011) 1.36
A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome. Am J Hum Genet (2005) 1.33
Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1. Am J Hum Genet (2002) 1.32
A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc Natl Acad Sci U S A (2001) 1.30
Protein interaction domain mapping of human kinetochore protein Blinkin reveals a consensus motif for binding of spindle assembly checkpoint proteins Bub1 and BubR1. Mol Cell Biol (2011) 1.30
Genetic analysis of susceptibility to dextran sulfate sodium-induced colitis in mice. Genomics (1999) 1.29
Mouse background strain profoundly influences Paneth cell function and intestinal microbial composition. PLoS One (2012) 1.19
Nutrigenomics and selenium: gene expression patterns, physiological targets, and genetics. Annu Rev Nutr (2008) 1.17
Dual oxidase in the intestinal epithelium of zebrafish larvae has anti-bacterial properties. Biochem Biophys Res Commun (2010) 1.15
Usefulness of the 5' region of the cDNA encoding acidic ribosomal phosphoprotein P0 conserved among rats, mice, and humans as a standard probe for gene expression analysis in different tissues and animal species. J Biochem Biophys Methods (2006) 1.13
Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest (2008) 1.12
Identification of novel cytosolic phospholipase A(2)s, murine cPLA(2){delta}, {epsilon}, and {zeta}, which form a gene cluster with cPLA(2){beta}. J Biol Chem (2005) 1.12
Isoforms of renal Na-K-2Cl cotransporter NKCC2: expression and functional significance. Am J Physiol Renal Physiol (2008) 1.08
Cd14, Gbp1, and Pla2g2a: three major candidate genes for experimental IBD identified by combining QTL and microarray analyses. Physiol Genomics (2006) 1.08
Identification of a sequence-specific single-stranded DNA binding protein that suppresses transcription of the mouse myelin basic protein gene. J Biol Chem (1995) 1.06
Microflora trigger colitis in mice deficient in selenium-dependent glutathione peroxidase and induce Gpx2 gene expression. Biol Chem (2003) 1.03
The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology. J Am Soc Nephrol (1999) 1.03
Lysosome biogenesis mediated by vps-18 affects apoptotic cell degradation in Caenorhabditis elegans. Mol Biol Cell (2008) 1.01
A Strong Impact of Genetic Background on Gut Microflora in Mice. Int J Inflam (2010) 0.99
Reduced microbial diversity and high numbers of one single Escherichia coli strain in the intestine of colitic mice. Environ Microbiol (2009) 0.97
Codanin-1 mutations in congenital dyserythropoietic anemia type 1 affect HP1{alpha} localization in erythroblasts. Blood (2011) 0.96
Adenosine: an immune modulator of inflammatory bowel diseases. World J Gastroenterol (2009) 0.95
Nrf2 gene promoter polymorphism is associated with ulcerative colitis in a Japanese population. Hepatogastroenterology (2008) 0.90
Interfacial kinetic and binding properties of mammalian group IVB phospholipase A2 (cPLA2beta) and comparison with the other cPLA2 isoforms. J Biol Chem (2010) 0.88
LAP2alpha-binding protein LINT-25 is a novel chromatin-associated protein involved in cell cycle exit. J Cell Sci (2007) 0.88
Characterization of large genomic deletions in the FBN1 gene using multiplex ligation-dependent probe amplification. BMC Med Genet (2011) 0.88
Colitis locus on chromosome 2 impacting the severity of early-onset disease in mice deficient in GPX1 and GPX2. Inflamm Bowel Dis (2010) 0.86
Cloning of a gene for a novel epithelium-specific cytosolic phospholipase A2, cPLA2delta, induced in psoriatic skin. J Biol Chem (2004) 0.86
Novel SPG11 mutations in Asian kindreds and disruption of spatacsin function in the zebrafish. Neurogenetics (2010) 0.85
Expression of lactoperoxidase in differentiated mouse colon epithelial cells. Free Radic Biol Med (2012) 0.79
Trichinella spiralis induces de novo expression of group IVC phospholipase A2 in the intestinal epithelium. Int J Parasitol (2007) 0.79
Expression and chromosomal mapping of mouse Gpx2 gene encoding the gastrointestinal form of glutathione peroxidase, GPX-GI. Biomed Environ Sci (1997) 0.78
Mapping of mouse obesity genes: A generic approach to a complex trait. J Nutr (1997) 0.77
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. FASEB J (2003) 3.44
Criteria for the use of omics-based predictors in clinical trials. Nature (2013) 3.15
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov (2012) 2.74
Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer (2007) 2.52
Oxidative innate immune defenses by Nox/Duox family NADPH oxidases. Contrib Microbiol (2008) 2.50
The Nox family of NAD(P)H oxidases: host defense and beyond. J Biol Chem (2004) 2.48
Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res (2004) 2.42
Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther (2010) 2.38
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res (2008) 2.08
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res (2010) 2.06
Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol (2013) 1.99
Phase III clinical trial development: a process of chutes and ladders. Clin Cancer Res (2010) 1.97
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer (2005) 1.89
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.87
Designing phase 0 cancer clinical trials. Clin Cancer Res (2008) 1.85
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med (2013) 1.84
Involvement of Rac1 in activation of multicomponent Nox1- and Nox3-based NADPH oxidases. Mol Cell Biol (2006) 1.80
Endoscopic clip closure versus surgery for the treatment of iatrogenic colon perforations developed during diagnostic colonoscopy: a review of 115,285 patients. Surg Endosc (2012) 1.80
Subcellular localization and function of alternatively spliced Noxo1 isoforms. Free Radic Biol Med (2006) 1.76
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res (2011) 1.76
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res (2008) 1.70
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2008) 1.70
Proteins homologous to p47phox and p67phox support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells. J Biol Chem (2003) 1.70
Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol (2004) 1.66
Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res (2010) 1.65
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv (2007) 1.64
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res (2009) 1.64
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther (2009) 1.60
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res (2008) 1.60
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle (2011) 1.60
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov (2010) 1.59
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther (2013) 1.55
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res (2012) 1.53
Advances in using PARP inhibitors to treat cancer. BMC Med (2012) 1.49
Genome-wide depletion of replication initiation events in highly transcribed regions. Genome Res (2011) 1.44
Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol (2006) 1.40
NAD(P)H oxidase 1, a product of differentiated colon epithelial cells, can partially replace glycoprotein 91phox in the regulated production of superoxide by phagocytes. J Immunol (2003) 1.38
Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol (2007) 1.37
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther (2009) 1.37
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Duox maturation factors form cell surface complexes with Duox affecting the specificity of reactive oxygen species generation. FASEB J (2008) 1.36
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A (2012) 1.35
The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells. J Immunol (2008) 1.35
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin Cancer Res (2010) 1.35
Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med (2012) 1.31
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res (2007) 1.27
Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor beta-dependent manner: a new contributor to HCV-induced oxidative stress. J Virol (2009) 1.27
Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS One (2011) 1.26
Diagnostic yield of tissue sampling using a bite-on-bite technique for incidental subepithelial lesions. Korean J Intern Med (2009) 1.25
Gastric Metastasis from Ovarian Adenocarcinoma Presenting as a Submucosal Tumor without Ulceration. Gut Liver (2009) 1.25
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res (2011) 1.22
Wee1 kinase as a target for cancer therapy. Cell Cycle (2013) 1.22
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther (2014) 1.19
Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation. BMC Bioinformatics (2008) 1.19
Efficacy and safety of endoscopic submucosal dissection for superficial squamous esophageal neoplasia: a meta-analysis. Dig Dis Sci (2014) 1.18
Pyocyanin effects on respiratory epithelium: relevance in Pseudomonas aeruginosa airway infections. Trends Microbiol (2012) 1.18
Expression of NADPH oxidase homologues and accessory genes in human cancer cell lines, tumours and adjacent normal tissues. Free Radic Res (2009) 1.16
Role of Se-dependent glutathione peroxidases in gastrointestinal inflammation and cancer. Free Radic Biol Med (2004) 1.16
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2007) 1.15
Epithelium-specific glutathione peroxidase, Gpx2, is involved in the prevention of intestinal inflammation in selenium-deficient mice. J Nutr (2005) 1.15
A regulated adaptor function of p40phox: distinct p67phox membrane targeting by p40phox and by p47phox. Mol Biol Cell (2006) 1.14
Endoscopic band ligation and endoscopic hemoclip placement for patients with Mallory-Weiss syndrome and active bleeding. World J Gastroenterol (2008) 1.13
Sequential binding of cytosolic Phox complex to phagosomes through regulated adaptor proteins: evaluation using the novel monomeric Kusabira-Green System and live imaging of phagocytosis. J Immunol (2008) 1.10
Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst (2011) 1.09
Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas. Nucl Med Biol (2013) 1.08
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res (2005) 1.07
The nonphagocytic NADPH oxidase Duox1 mediates a positive feedback loop during T cell receptor signaling. Sci Signal (2010) 1.06
Unique targeting of cytosolic phospholipase A2 to plasma membranes mediated by the NADPH oxidase in phagocytes. J Cell Biol (2003) 1.05
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res (2003) 1.05
Double-stranded RNA induces shedding of the 34-kDa soluble TNFR1 from human airway epithelial cells via TLR3-TRIF-RIP1-dependent signaling: roles for dual oxidase 2- and caspase-dependent pathways. J Immunol (2010) 1.04
The prevalence of gastrointestinal symptoms in patients with non-insulin dependent diabetes mellitus. Korean J Intern Med (2009) 1.04
Analysis of mRNA transcripts from the NAD(P)H oxidase 1 (Nox1) gene. Evidence against production of the NADPH oxidase homolog-1 short (NOH-1S) transcript variant. J Biol Chem (2004) 1.04
Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases. Nat Prod Rep (2014) 1.04
Up-regulation and sustained activation of Stat1 are essential for interferon-gamma (IFN-gamma)-induced dual oxidase 2 (Duox2) and dual oxidase A2 (DuoxA2) expression in human pancreatic cancer cell lines. J Biol Chem (2011) 1.03
Microflora trigger colitis in mice deficient in selenium-dependent glutathione peroxidase and induce Gpx2 gene expression. Biol Chem (2003) 1.03
Novel sources of reactive oxygen species in the human body. Nephrol Dial Transplant (2007) 1.02
Pyocyanin-enhanced neutrophil extracellular trap formation requires the NADPH oxidase. PLoS One (2013) 1.02
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res (2003) 1.02
Allele-specific H3K79 Di- versus trimethylation distinguishes opposite parental alleles at imprinted regions. Mol Cell Biol (2010) 1.01
Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors? J Clin Oncol (2010) 1.01
Mechanism of angiotensin II-induced superoxide production in cells reconstituted with angiotensin type 1 receptor and the components of NADPH oxidase. J Biol Chem (2007) 1.01
Phase 0 clinical trials: conceptions and misconceptions. Cancer J (2008) 1.01
Safety and feasibility of targeted agent combinations in solid tumours. Nat Rev Clin Oncol (2013) 1.01
The role of bioactive compounds on the promotion of neurite outgrowth. Molecules (2012) 1.00
Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res (2006) 1.00
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res (2003) 1.00
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst (2013) 0.99
A Strong Impact of Genetic Background on Gut Microflora in Mice. Int J Inflam (2010) 0.99
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer (2004) 0.99
Development and use of integral assays in clinical trials. Clin Cancer Res (2012) 0.99
Mutation accumulation in the intestine and colon of mice deficient in two intracellular glutathione peroxidases. Cancer Res (2006) 0.99
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res (2004) 0.99